NX Development Corp.   Report issue

For profit Phase 3
Founded: Louisville KY United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2020
NCT04305470
First Marketed Drug
2017
aminolevulinic acid (levulan)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

NXDC | NX Development Corp

Active Ingredients

Marketed Drugs (1)

aminolevulinic acid (levulan) (2017)

Drugs in Phase 3 Trials (1)

aminolevulinic acid (levulan) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Meningioma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1